Literature DB >> 15472530

Fatal staphylococcal sepsis in Crohn's disease after infliximab.

Klaus R Herrlinger1, Annette Borutta, Gabriel Meinhardt, Eduard F Stange, Klaus Fellermann.   

Abstract

We report a case of a 40-year-old woman who had received infliximab for perianal Crohn's disease. After six infusions of infliximab, the patient developed staphylococcal pneumonia resulting in fatal adult respiratory distress syndrome. The case is discussed in the context of the toxicity profile of infliximab. Copyright 2004 Lippincott Williams & Wilkins

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15472530     DOI： 10.1097/00054725-200409000-00024

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN： 1078-0998            Impact factor:   5.325


  5 in total

1.  Complications of tumor necrosis factor-α blockade in chronic granulomatous disease-related colitis.

Authors:  Gulbu Uzel; Jordan S Orange; Nina Poliak; Beatriz E Marciano; Theo Heller; Steven M Holland
Journal:  Clin Infect Dis       Date:  2010-11-08       Impact factor: 9.079

2.  Anti-TNFα antibody infliximab treatment for an infant with fistulising Crohn's disease.

Authors:  Omar I Saadah
Journal:  BMJ Case Rep       Date:  2010-01-13

3.  Fatal group A Streptococcus purpura fulminans in a child receiving TNF-α blocker.

Authors:  Christian Renaud; Philippe Ovetchkine; Patricia Bortolozzi; Claire Saint-Cyr; Bruce Tapiero
Journal:  Eur J Pediatr       Date:  2010-11-10       Impact factor: 3.183

4.  Oral infection control to assist infliximab therapy in a Behçet's disease patient with severe eye inflammation in response to dental treatment: a case report.

Authors:  Chieko Kudo; Hiroshi Wakabayashi; Masayuki Shimoe; Hiroya Kobayashi; Takashi Ito; Toshinori Ohkawa; Arisa Isoshima-Nakamura; Junji Mineshiba; Norie Yoshioka; Kumiko Nawachi; Hiroshi Maeda; Toshihiko Matsuo; Hirofumi Makino; Shogo Takashiba
Journal:  Clin Case Rep       Date:  2014-09-04

5.  Multiple liver abscesses in Crohn's disease in infliximab therapy, successfully treated with antibiotic therapy.

Authors:  E Otheo; A de Blas; J Fortún; C Camarero
Journal:  Rev Esp Quimioter       Date:  2019-10-29       Impact factor: 1.553
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.